. .

Stephen M. Apatow
Director of Research and Development 
Humanitarian Resource Institute Biodefense Reference Library
Foreign Animal and Zoonotic Disease Center
Eastern USA: (203) 668-0282   Western USA: (775) 884-4680
Internet: http://www.humanitarian.net/biodefense/fazdc/
Email: s.m.apatow@humanitarian.net

SAFETY AND IMMUNOGENICITY OF MAMMALIAN CELL CULTURE DERIVED VACCINE

Potential contamination of A-Fujian-H3N2 strain grown successfully in Madin Darby Canine Kidney (MDCK) cells following unsuccessful attempts to harvest virus through inoculation of chorionallantoic tissue, has prompted discussion regarding the safety and immunogenicity of mammalian cell culture derived vaccine.

Related Research: National Library of Medicine

• Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine. 2002 Jan 15;20(7-8):1240-7. PubMED Abstract.
• A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol Stand. 1999;98:127-32; discussion 133-4. PubMED Abstract.
• Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand. 1999;98:93-100; discussion 111. PubMED Abstract.
• Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis. 1997 Aug;176 Suppl 1:S20-3. PubMED Abstract.